Effect of Omega-3 fatty acid added to parenteral nutrition on inflammatory in preterm infants
Main Article Content
Keywords
Keywords: Omega-3 fattyacid, inflammation markers, prematüre, parenteral nutrition
Abstract
Objective: This study aimed to investigate the effect of omega-3 fatty acid addition to Total Parenteral Nutrition (TPN) on the inflammatory process and clinical outcomes. Methods: The study included 51 infants who were in the Neonatal Intensive Care Unit (NICU) and fed by TPN for minimum 10 days, with a gestational age of ≤32 weeks and a birth weight of ≤2500 g. The preterm infants fed by TPN with 80% omega-9 and 20% omega-6 fatty acids were determined as Group 1(n:26) and by TPN with added omega-3 fatty acid (1.0g/day) as Group 2 (n:25). This retrospective study retrieved demographic characteristics, anthropometric measurements, nutrition therapy details, comorbidity development, inflammatory markers, and laboratory and clinical results from patient files. Those who received exchange transfusions and who received TPN for less than 10 days were excluded from the study. Results: Comorbidity developed in 35% of Group 1 and 28% of Group 2, with no difference between the groups (p < 0.05). There was no difference in gestational week at birth, birth weight, duration of mechanical ventilation (MV), duration of oxygen support, and
maternal age between the two groups (p < 0.05). There was no difference in the carbohydrate (CH), protein and lipid levels, and glucose infusion rate (GIH) between the two groups (p <0.05). In Group 2, the daily amount of omega-3 fatty acid was increased by 1.0±0.1 g/day, accounting for 7.7±0.03% of the total energy. There was a significant decrease in the blood levels of Aspartate Aminotransferase (AST) and Total Bilirubin (T.Bil) on day 10 in Group 2 (p < 0.05). Procalcitonin (PCT) significantly decreased on days 1, 4, 7, and 10 in both groups (p < 0.05). The difference in C-Reactive Protein (CRP) on days 4 and 10, and PCT and Neutrophil-to-Lymphocyte Ratio (NLR) on days 1, 4, 7, 10 was insignificant, with lower values in Group 2. Conclusion: The present study established a low level of positive changes in inflammatory findings and a decrease in liver function test results with the addition of fish oil to TPN. The different fatty acid contents of ILEs, the optimum ratio between the fatty acids, and the amount and duration of use affect the clinical outcomes. Further studies are needed to determine a safe, adequate dose and appropriate fatty acid profile.
References
2. Lapillonne A, Berleur MP, Brasseur Y, Calvez S. Safety of parenteral nutrition in newborns: Results from a nation wide prospective cohort study. Clin Nut. 2018;37:624-629.
3. Power VA, Spittle AJ, Lee KJ, Anderson P, Thompson DK, Doyle LW et al. Nutrition, Growth, Brain Volume, and Neurodevelopment in Very Preterm Children. J Pediatr. 2019;215:50-55.
4. Roggero P, Liotto N, Menis C, Mosca F. New Insights in Preterm Nutrition. Nutr. 2020;12:1857-1861.
5. Lapillonne A, Groh-Wargo S, Gonzalez CH, Uauy R. Lipid needs of preterm infants: updated recommendations. J Pediatr. 2013;162:37–47.
6. Lapillonne A, Moltu SJ. Long-Chain Polyunsaturated Fatty Acids and Clinical Outcomes of Preterm Infants. Ann Nutr Metab. 2016;69(suppl 1):36–44.
7. Lapillonne A, Mis NF, Goulet O, Akker CHP, Wu J, Koletzko B. ESPGHAN/ESPEN/ESPR/CSPEN guidelines on pediatric parenteral nutrition: Lipids. Clin Nutr. 2018;37:2324-2336.
8. Tian H, Lu Y, Shah SP, Hong S. Autacoid 14S, 21R-dihydroxy-docosahexaenoic acid counter acts diabetic impairment of macrophage prohealing functions. Am J Pathol. 2011;179:1780–1791.
9. Klek S. Omega-3 Fatty Acids in Modern Parenteral Nutrition: A Review of the Current Evidence. J Clin Med. 2016;5:34-50.
10. Hacımustafaoglu M. Procalcitonin as aacute phase reactant. J Pediatr Inf. 2017;11(4): 196-215.
11. Westerdijk K, Simons KS, Zegers M, Wever PC, Pickkers P, Jager CPC. The value of the neutrophil-lymphocyte count ratio in the diagnosis of sepsis in patients admitted to the Intensive Care Unit: Are rospective cohort study. PLOS ONE | https://doi.org/10.1371/journal.pone.0212861 February 27.2019;1-13.
12. Eraldemir FC. Neutrophil/Lymphocyte Ratio Instead of Procalcitonin: Is it an Option? Turkish JClinic Biochem. 2018;16(1):11-16.
13. Guthrei G, Premkumar M, Burrin DG. Emerging clinical benefits of new-generation fat emulsions in preterm neonates. Nutr Clin Pract. 2017;32(33):326-336.
14. Unal S, Ulubas D I, Arifoglu I, Erol S, Demirel N, Bas AY. Evaluation of Liver Function Tests in Preterm Infants Receiving Parenteral Lipid Emulsions Based on Fish Oil or Olive Oil. Turkish J Pediatr Dis. 2018;2:124-130.
15. Yildizdas H, Poyraz B, Atlı G, Sertdemir Y, Mert K, Özlü F. et al. Effects of two different lipid emulsions on antioxidant status, lipid peroxidation and parenteral nutrition- related cholestasis in premature babies, a randomized-controlled study. Pediatr and Neo. 2019; 60:359-367.
16. D’Ascenzo R, Savini S, Biagetti C, Bellagamba MP, Marchionni P, Pompilio A, et al. Higher docosahexaenoic acid, lower arachidonic acid and reduced lipid tolerance with high doses of a lipid emulsion containing 15% fish oil: A randomized clinical trial. Clin Nutr. 2014;33:1002-1011.
17. Savini S, D’Ascenzo R, Biagetti C, Serpentini G, Pompilio AB, Cogo PE. et al. The effect of 5 intravenous lipid emulsions on plasma phytosterols in preterm infants receiving parenteral nutrition: a randomized clinical trial. Am J Clin Nutr. 2013;98(2):312–318.
18. Zhao Y, Wu Y, Pei J, Chen Z, Wang Q, Xiang B. Safety and efficacy of parenteral fish oil – containing lipid emulsions in prematüre neonates. J Pediatr Gastroenterogy Nutr. 2015;60:708-716.
19. Yakah W, Cortijo DR, Singh P, Browm J, Stoll B, Kulkarni M. et al. Parenteral fish-oil contaning lipid emülsions limit initial lipopolysaccharide-ınduced host immune responses in preterm pigs. Nutr. 2021;13:205-223.
20. Housny M, Nahas R, Sheeren A, Elshafei SA, Kahaled H. Impact of oral omega-3 fatty acids supplementation in early sepsis on clinical outcome and immunomodulation. The Eygptian J Crit care med. 2013;1:119-126.
21. Klek S, Wierzbicka DM, Scislo L, Walewska E, Pietka M, Sczepanek K. High Dose Intravenous Fish Oil Reduces Inflammation—A Retrospective Tale from Two Centers. Nutrients. 2020;12(9):2865-2873.
22. Makrides M, Gibson RA, McPhee AJ, Collins CT, Davis PG, Doyle LW. et al. Neurodevelopmental outcomes of preterm infants fed high-dose docosahexaenoic acid: a randomized controlled trial. JAMA. 2009;301(2):175–182.
23. Dasilva G, Pazos M, García-Egido E, Gallardo JM, Rodríguez I, Cela R, et al. Healthy effect of different proportions of marine ω-3 PUFAs EPA and DHA supplementation in wistarrats: Lipidomicbio markers of oxidative stress and inflammation. J Nutr Biochem. 2015;26(11):1385-92.
24. Vanek WV, Seidner DL, Bistrain B, Gura K, Allen P, Collier S. et al. ASPEN position paper: clinial role for alternative intravenous fat emulsions. Nutr Clin Pract. 2012;27(2):150-192.
25. Calkins KL, Robinson DT. Intravenous lipid emulsions in the NICU. http://neoreviews.aappublications.org/ at Bibliotheque Univ Paris. 2020;(2)21:109-119.
26. Edward RR, Innes JK, Marino VL, Calder FC. Influence different intravenous lipid emulsions on growth, development and laboratory and clinical outcomes in hospitalized pediatric patients: A systematic review. Clinical Nutr. 2018;37:765-783
27. Aydın I, Agıllı M, Aydın FN, Kurt YG, Çaycı T, Tas A. et al. The reference ranges of neutrophil-lymphocyte ratio in different age groups. Gulhane Medical Journal. 2015;57:414-418.
28. Serhan CN, Chiang N, Dyke TE. Resolving inflammation: Dual anti-inflammatory and pro-resolution lipid mediators. Nat. Rev. Immunol. 2008;8:349–361.
29. Gabbs, M, Leng S, Devassy JG, Monirujjaman M, Aukema HM. Advances in Our Understanding of Oxylipins Derived from Dietary PUFAs. Adv. Nutr. 2015;6(5):513–540.
30. Harauma A, Yasuda H, Hatanaka, E, Nakamura MT, Salem, NJ, Moriguchi T. The essentiality of arachidonic acid in addition to docosahexaenoic acid for brain growth and function. Prostaglandins Leukot. Essent. Fatty Acids. 2017;116:9–18.
31. Kapoor V, Malviya MN, Soll R. Lipid emulsions for parenterally fed preterm infants. Cochrane database of Syst Rev. 2019;(4)6:6:1-189.
32. Deshpande GC, Cai W. Use of Lipids in Neonates Requiring Parenteral Nutrition. ASPEN. 2020;44(1):45-54.
33. Cury-Boaventura MF, Gorjao R, Lima TM, Piva TM, Peres CM, Soriano FG. et al. Toxicity of a soybean oli emulsion on human lymphocytes and neutrophils. JPEN Journal enteral parenteral nutrition. 2006;30(2):115-23.
34. Granato D, Blum S, Rössle C, Boucher JL, Malnoe A, Dutot G. Effects of parenteral lipid emulsions with different fatty acid composition on immune cell functions in vitro. JPEN Journal parenteral enteral nutrition. 2000;24(2):113-118.
35. Povroznik JM, Engler-Chiurazzi EB, Nanavati T, Pergami P. Absolute lymphocyte and neutrophil counts in neonatal ischemic brain injury. Sage Open Med. 2018;6:1-7.
36. Sorensen LS, Thorlacius-Ussing O, Rasmussen HH, Lundbye-Christensen S, Calder PC, Lindorff-Larsen K. et al. Effects of perioperative supplementation with omega-3 fatty acids on leukotriene B(4) and leukotriene B(5) production by stimulated neutrophils in patients with colorectal cancer: A randomized, placebo-controlled intervention trial. Nutrients. 2014;6:4043–4057.
37. Pichler J, Simchowitz V, Macdonald S, Hill S. Comparison of liver function with two new/mixed intravenous lipid emulsions in children with intestinal failure. Eurp. J Clinic Nutr. 2014;68(10):1161–1167.
38. Madnavat H, Welu AL, Gilbert EJ, Taylor DB, Jain S, Manithody C. et al. Mechanism of parenteral nutrition associated liver and gut injury. Nutr Clinic Prac. 2020;35(1):63-71.
39. Robertson, R. Omega-3-6-9 Fatty Acids: A complete overview. https://www.healthline.com/nutrition/omega-3-6-9-overview. 2018 [Accessed: 21 February 2021]
40. Saini RK, Keum YS. Omega-3 and omega-6 polyunsaturated fatty acids: Dietary sources, metabolism, and significance-A review. Life Science. 2018;203:255-268.
41. Arnordttir H, Pawelzik SC, Sarajlic P, Quaranta A, Kolmert J, Religa D et al. Immunomodulation by ıntravenous omega-3 fatty acid treatment in older subject hospitalized for Covid-19: a single-blind randomized controlled trial. The preprint server for health sciences. Medrxiv preprint. https://doi.org/10.1101/2021.12.27.21268264
42. Guthrie G, Burrin D. Impact of parenteral lipid emulsion compenents on cholestatic liver disease in neonates. Nutr. 2021;13(2):508-527.
Article Sidebar
Article Details
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
